Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Dominic M. Walsh, Ph.D.

Co-Author

This page shows the publications co-authored by Dominic Walsh and Dennis Selkoe.
Connection Strength

8.903
  1. Amyloid ß-protein and beyond: the path forward in Alzheimer's disease. Curr Opin Neurobiol. 2020 04; 61:116-124.
    View in: PubMed
    Score: 0.904
  2. A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration. Nat Rev Neurosci. 2016 Apr; 17(4):251-60.
    View in: PubMed
    Score: 0.685
  3. The APP family of proteins: similarities and differences. Biochem Soc Trans. 2007 Apr; 35(Pt 2):416-20.
    View in: PubMed
    Score: 0.367
  4. A beta oligomers - a decade of discovery. J Neurochem. 2007 Jun; 101(5):1172-84.
    View in: PubMed
    Score: 0.363
  5. The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention. Biochem Soc Trans. 2005 Nov; 33(Pt 5):1087-90.
    View in: PubMed
    Score: 0.333
  6. Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation. J Neurosci. 2005 Mar 09; 25(10):2455-62.
    View in: PubMed
    Score: 0.318
  7. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron. 2004 Sep 30; 44(1):181-93.
    View in: PubMed
    Score: 0.309
  8. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett. 2004 Jun; 11(3):213-28.
    View in: PubMed
    Score: 0.302
  9. gamma-Secretase cleavage and binding to FE65 regulate the nuclear translocation of the intracellular C-terminal domain (ICD) of the APP family of proteins. Biochemistry. 2003 Jun 10; 42(22):6664-73.
    View in: PubMed
    Score: 0.282
  10. Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem Soc Trans. 2002 Aug; 30(4):552-7.
    View in: PubMed
    Score: 0.266
  11. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002 Apr 04; 416(6880):535-9.
    View in: PubMed
    Score: 0.260
  12. The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry. 2000 Sep 05; 39(35):10831-9.
    View in: PubMed
    Score: 0.233
  13. Dynamics of plasma biomarkers in Down syndrome: the relative levels of Aß42 decrease with age, whereas NT1 tau and NfL increase. Alzheimers Res Ther. 2020 03 19; 12(1):27.
    View in: PubMed
    Score: 0.226
  14. miR-212 and miR-132 Are Downregulated in Neurally Derived Plasma Exosomes of Alzheimer's Patients. Front Neurosci. 2019; 13:1208.
    View in: PubMed
    Score: 0.221
  15. Target engagement in an alzheimer trial: Crenezumab lowers amyloid ß oligomers in cerebrospinal fluid. Ann Neurol. 2019 08; 86(2):215-224.
    View in: PubMed
    Score: 0.214
  16. Identification of neurotoxic cross-linked amyloid-ß dimers in the Alzheimer's brain. Brain. 2019 05 01; 142(5):1441-1457.
    View in: PubMed
    Score: 0.212
  17. Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer's disease. Alzheimers Dement. 2019 03; 15(3):487-496.
    View in: PubMed
    Score: 0.205
  18. An in vitro paradigm to assess potential anti-Aß antibodies for Alzheimer's disease. Nat Commun. 2018 07 11; 9(1):2676.
    View in: PubMed
    Score: 0.201
  19. Detection of Aggregation-Competent Tau in Neuron-Derived Extracellular Vesicles. Int J Mol Sci. 2018 Feb 27; 19(3).
    View in: PubMed
    Score: 0.196
  20. Large Soluble Oligomers of Amyloid ß-Protein from Alzheimer Brain Are Far Less Neuroactive Than the Smaller Oligomers to Which They Dissociate. J Neurosci. 2017 01 04; 37(1):152-163.
    View in: PubMed
    Score: 0.181
  21. C-Terminally Truncated Forms of Tau, But Not Full-Length Tau or Its C-Terminal Fragments, Are Released from Neurons Independently of Cell Death. J Neurosci. 2015 Jul 29; 35(30):10851-65.
    View in: PubMed
    Score: 0.163
  22. A highly sensitive novel immunoassay specifically detects low levels of soluble Aß oligomers in human cerebrospinal fluid. Alzheimers Res Ther. 2015; 7(1):14.
    View in: PubMed
    Score: 0.160
  23. Secreted amyloid ß-proteins in a cell culture model include N-terminally extended peptides that impair synaptic plasticity. Biochemistry. 2014 Jun 24; 53(24):3908-21.
    View in: PubMed
    Score: 0.152
  24. New ELISAs with high specificity for soluble oligomers of amyloid ß-protein detect natural Aß oligomers in human brain but not CSF. Alzheimers Dement. 2013 Mar; 9(2):99-112.
    View in: PubMed
    Score: 0.138
  25. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A. 2011 Apr 05; 108(14):5819-24.
    View in: PubMed
    Score: 0.121
  26. Isolation of low-n amyloid ß-protein oligomers from cultured cells, CSF, and brain. Methods Mol Biol. 2011; 670:33-44.
    View in: PubMed
    Score: 0.119
  27. beta-Secretase cleavage is not required for generation of the intracellular C-terminal domain of the amyloid precursor family of proteins. FEBS J. 2010 Mar; 277(6):1503-18.
    View in: PubMed
    Score: 0.112
  28. Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Abeta assembly forms throughout life. Neurobiol Dis. 2009 Nov; 36(2):293-302.
    View in: PubMed
    Score: 0.108
  29. Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron. 2009 Jun 25; 62(6):788-801.
    View in: PubMed
    Score: 0.107
  30. A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol. 2009 Feb; 66(2):190-9.
    View in: PubMed
    Score: 0.104
  31. gamma-secretase processing of APLP1 leads to the production of a p3-like peptide that does not aggregate and is not toxic to neurons. Brain Res. 2009 Mar 25; 1262:89-99.
    View in: PubMed
    Score: 0.104
  32. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008 Aug; 14(8):837-42.
    View in: PubMed
    Score: 0.100
  33. Aggregation and catabolism of disease-associated intra-Abeta mutations: reduced proteolysis of AbetaA21G by neprilysin. Neurobiol Dis. 2008 Sep; 31(3):442-50.
    View in: PubMed
    Score: 0.100
  34. Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. Am J Pathol. 2007 Jul; 171(1):241-51.
    View in: PubMed
    Score: 0.093
  35. Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. Ann Neurol. 2006 Dec; 60(6):668-76.
    View in: PubMed
    Score: 0.090
  36. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol. 2006 Apr 15; 572(Pt 2):477-92.
    View in: PubMed
    Score: 0.085
  37. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron. 2003 Dec 18; 40(6):1087-93.
    View in: PubMed
    Score: 0.073
  38. The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron. 2003 Feb 20; 37(4):583-95.
    View in: PubMed
    Score: 0.069
  39. In vitro studies of amyloid beta-protein fibril assembly and toxicity provide clues to the aetiology of Flemish variant (Ala692-->Gly) Alzheimer's disease. Biochem J. 2001 May 01; 355(Pt 3):869-77.
    View in: PubMed
    Score: 0.061
  40. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci. 1999 Oct 15; 19(20):8876-84.
    View in: PubMed
    Score: 0.055
  41. Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J Biol Chem. 1999 Sep 03; 274(36):25945-52.
    View in: PubMed
    Score: 0.054
  42. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem. 1998 Dec 04; 273(49):32730-8.
    View in: PubMed
    Score: 0.052
  43. MicroRNA-132 provides neuroprotection for tauopathies via multiple signaling pathways. Acta Neuropathol. 2018 10; 136(4):537-555.
    View in: PubMed
    Score: 0.050
  44. Oligomerization of endogenous and synthetic amyloid beta-protein at nanomolar levels in cell culture and stabilization of monomer by Congo red. Biochemistry. 1998 Mar 17; 37(11):3602-11.
    View in: PubMed
    Score: 0.049
  45. Soluble Aß oligomers impair hippocampal LTP by disrupting glutamatergic/GABAergic balance. Neurobiol Dis. 2016 Jan; 85:111-121.
    View in: PubMed
    Score: 0.042
  46. The familial Alzheimer's disease APPV717I mutation alters APP processing and Tau expression in iPSC-derived neurons. Hum Mol Genet. 2014 Jul 01; 23(13):3523-36.
    View in: PubMed
    Score: 0.037
  47. The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain. 2010 May; 133(Pt 5):1328-41.
    View in: PubMed
    Score: 0.028
  48. Aß oligomers inhibit synapse remodelling necessary for memory consolidation. Neurobiol Aging. 2011 Dec; 32(12):2211-8.
    View in: PubMed
    Score: 0.028
  49. Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci. 2008 Apr 16; 28(16):4231-7.
    View in: PubMed
    Score: 0.025
  50. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. 2007 Mar 14; 27(11):2866-75.
    View in: PubMed
    Score: 0.023
  51. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med. 2005 May; 11(5):556-61.
    View in: PubMed
    Score: 0.020
  52. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci. 2005 Jan; 8(1):79-84.
    View in: PubMed
    Score: 0.020
  53. Amyloid beta-protein induced electrophysiological changes are dependent on aggregation state: N-methyl-D-aspartate (NMDA) versus non-NMDA receptor/channel activation. Neurosci Lett. 2004 Aug 19; 366(3):320-5.
    View in: PubMed
    Score: 0.019
  54. Soluble Arctic amyloid beta protein inhibits hippocampal long-term potentiation in vivo. Eur J Neurosci. 2004 May; 19(10):2839-46.
    View in: PubMed
    Score: 0.019
  55. Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J Neurosci. 2004 Mar 31; 24(13):3370-8.
    View in: PubMed
    Score: 0.019
  56. A de novo designed helix-turn-helix peptide forms nontoxic amyloid fibrils. Nat Struct Biol. 2000 Dec; 7(12):1095-9.
    View in: PubMed
    Score: 0.015
  57. An improved method of preparing the amyloid beta-protein for fibrillogenesis and neurotoxicity experiments. Amyloid. 2000 Sep; 7(3):166-78.
    View in: PubMed
    Score: 0.015
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.